Video

Dr. Yuh on Outcomes Between RT and Surgery in Prostate Cancer

Author(s):

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

It is very difficult to compare radiation therapy and surgery in a clinical trial, Yuh explains. This is because, he adds, it is challenging to tell a patient they are going to undergo surgery instead of radiation therapy, or vice versa.

Because of this, Yuh observed that patients who undergo surgery have different characteristics than patients who undergo radiation treatments. Although it is difficult to compare them both side by side, he adds that both treatments are effective and play a major role in the management of patients.

There may be certain patients who would be better served by 1 treatment or another, depending on their individual biases. Additionally, there are some patients who may be against surgery or radiation therapy, for example. Therefore, it is important for oncologists to be aware of patient preferences.

Related Videos
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health